References
Scully C, Diz Dios P, Kumar N. Special Care in Dentistry.London: Elsevier; 2007
Office for National Statistics.England: Cancer Registration Statistics; 2015
Lymphoma Action. What is lymphoma?. 2016. https://www.lymphomas.org.uk/about-lymphoma/what-is-lymphoma
Cesarman E. Pathology of lymphoma in HIV. Curr Opin Oncol. 2013; 25:487-494
Knight JS, Tsodikov A, Cibrik DM, Ross CW, Kaminski MS, Blayney DW. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. J Clin Oncol. 2009; 27:3354-3362
Chiu Y-H, Chung C-H, Lin K-T, Lin C-S, Chen J-H, Chen H-C Predictable biomarkers of developing lymphoma in patients with Sjögren syndrome: a nationwide population-based cohort study. Oncotarget. 2017; 8:50098-50108
Zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P, Santesson L. Epstein–Barr virus in Burkitt's lymphoma and nasopharyngeal carcinoma: EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature. 1970; 228:1056-1058
Dong HY, Harris NL, Preffer FI, Pitman MB. Fine-needle aspiration biopsy in the diagnosis and classification of primary and recurrent lymphoma: a retrospective analysis of the utility of cytomorphology and flow cytometry. Mod Pathol. 2001; 14:472-481
Delbeke D. Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma. J Nucl Med. 1999; 40:591-603
Albano D, Patti C, La Grutta L, Agnello F, Grassedonio E, Mulè A Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas. Eur J Radiol. 2016; 85:313-318
Alzahrani M, El-Galaly T, Hutchings M, Hansen J, Loft A, Johnsen H The value of routine bone marrow biopsy in patients with diffuse large B-cell lymphoma staged with PET/CT: a Danish-Canadian study. Ann Oncol. 2016; 27:1095-1099
Hartge P, Devesa SS, Fraumeni JF. Hodgkin's and non-Hodgkin's lymphomas. Canc Surv. 1993; 19:423-453
Urquhart A, Berg R. Hodgkin's and non-Hodgkin's lymphoma of the head and neck. Laryngoscope. 2001; 111:1565-1569
Sakula A. Dr Thomas Hodgkin and Sir Moses Montefiore Bart – the friendship of two remarkable men. J R Soc Med. 1979; 72:382-387
Kanzler H, Küppers R, Hansmann M-L, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996; 184:1495-1505
Küppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Ann Rev Immunol. 1998; 16:471-493
Lymphoma: Pathology, Diagnosis, and Treatment. In: Marcus R, Sweetenham JW, Williams ME (eds). Cambridge: Cambridge University Press; 2013
Haas R, Poortmans P, De Jong D, Aleman B, Dewit L, Verheij M High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003; 21:2474-2480
Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996; 14:1282-1290
London Cancer. Guidelines for the management of Lymphoma 2014. http://www.londoncancer.org/media/84337/london-cancer-lymphoma-radiotherapy-guidelines.pdf
Cartron G, Solal-Céligny P. Monoclonal Antibodies for Lymphoma.: Springer; 2013
Cheung MC, Haynes AE, Meyer RM, Stevens A, Imrie KR. Rituximab in lymphoma: a systematic review and consensus practice guideline from Cancer Care Ontario. Canc Treat Rev. 2007; 33:161-176
Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. 2008; 111:5486-5495
Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012; 119:5126-5132
Barbee MS, Ogunniyi A, Horvat TZ, Dang T-O. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology. Ann Pharma. 2015; 49:907-937
van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006; 108:3295-3301
Lymphoma Association. Supporting people affecting by lymphatic cancer 2016 (25/09/2017). https://www.lymphomas.org.uk
Aghaloo TL, Tetradis S. Osteonecrosis of the jaw in the absence of antiresorptive or antiangiogenic exposure: a series of 6 cases. J Oral Maxillofac Surg. 2017; 75:129-142
Keribin P, Guerrot D, Jardin F, Moizan H. Osteonecrosis of the jaw in a patient presenting with post-transplantation lymphoproliferative disorder treated with rituximab: a case report. J Oral Maxillofac Surg. 2017; 75:2599-2605
SDCEP. Oral Health Management of Patient at Risk of Medication-related Osteonecrosis of the Jaw. 2017. http://www.sdcep.org.uk/wp-content/uploads/2017/04/SDCEP-Oral-Health-Management-of-Patients-at-Risk-of-MRONJ-Guidance-in-Brief.pdf (cited 01/09/2017)
SDCEP. Dental advice for patients prescribed anti-resorptive drugs for the treatment of osteoporosis or other non-malignant diseases of bone. Scottish Dental Clinical Effectiveness Programme 2017. http://www.sdcep.org.uk/wp-content/uploads/2017/04/SDCEP-MRONJ-Information-for-Osteoporosis-Patients.pdf
Chemotherapy-induced myelosuppression. Semin Oncol Nurs. 1992; 8:113-123
Nizarali N, Rafique S. Special Care Dentistry: Part 2. Dental management of patients with drug-related acquired bleeding disorders. Dent Update. 2013; 40:711-718
Deotare U, Al-Dawsari G, Couban S, Lipton J. G-CSF-primed bone marrow as a source of stem cells for allografting: revisiting the concept. Bone Marrow Transplant. 2015; 50:1150-1156
Tay J, Levesque J-P, Winkler IG. Cellular players of hematopoietic stem cell mobilization in the bone marrow niche. Int J Hematol. 2017; 105:129-140
Scully C, Dios PD, Kumar N. Special Care In Dentistry: Handbook of Oral Healthcare.London: Elsevier Health Sciences; 2006
Peterson DE, Öhrn K, Bowen J, Fliedner M, Lees J, Loprinzi C Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Supportive Care Cancer. 2013; 21:327-332
Burke MC, Fenlon MR, Banerjee A. The role of the general dental practitioner in managing the oral care of head and neck oncology patients. Dent Update. 2012; 39:694-702
Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment. Cancer. 2005; 104:1129-1137
Nabil S, Samman N. Incidence and prevention of osteoradionecrosis after dental extraction in irradiated patients: a systematic review. Int J Oral Maxillofac Surg. 2011; 40:229-243
American Cancer Society. Radiation Therapy for Hodgkin Lymphoma. 2017. https://www.cancer.org/cancer/hodgkin-lymphoma/treating/radiation.html
Delanian S, Lefaix J. Reversibility of radiation-induced fibroatrophy. La Revue de Médecine Interne. 2002; 23:164-174
Kielbassa AM, Hinkelbein W, Hellwig E, Meyer-Lückel H. Radiation-related damage to dentition. Lancet Oncol. 2006; 7:326-335
Kaae JK, Stenfeldt L, Eriksen JG. Xerostomia after radiotherapy for oral and oropharyngeal cancer: increasing salivary flow with tasteless sugar-free chewing gum. Front Oncol. 2016; 6
Hahnel S, Behr M, Handel G, Bürgers R. Saliva substitutes for the treatment of radiation-induced xerostomia – a review. Supp Care Canc. 2009; 17:1331-1343
Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007; 109:820-831
Ezdinli EZ, Stutzman L, Aungst CW, Firat D. Corticosteroid therapy for lymphomas and chronic lymphocytic leukemia. Cancer. 1969; 23:900-909
Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroent. 2001; 33:289-294
Baron R, Ferrari S, Russell RGG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. 2011; 48:677-692
Masoodi NA. Oral bisphosphonates and the risk for osteonecrosis of the jaw. Br J Med Pract. 2009; 2:11-15
United Kingdom Medicines Information (UKMI). What steroid supplementation is required for a patient with primary adrenal insufficiency undergoing a dental procedure?. 2012. https://www.sps.nhs.uk/wp-content/uploads/2014/04/NW-QA-323.3-Steroid-supplementation-for-patients-with-adrenal-insufficiency-.pdf (cited 01/09/2017)
Gibson N, Ferguson J. Steroid cover for dental patients on long-term steroid medication: proposed clinical guidelines based upon a critical review of the literature. Br Dent J. 2004; 197:681-685
Hatzimichael E, Tuthill M. Hematopoietic stem cell transplantation. Stem Cells Cloning. 2010; 3:105-117
Ferrara JL, Levine JE, Reddy P, Holler E. Graft-versus-host disease. Lancet. 2009; 373:1550-1561
Sonis S, Kunz A. Impact of improved dental services on the frequency of oral complications of cancer therapy for patients with non-head-and-neck malignancies. Oral Surg Oral Med Oral Pathol. 1988; 65:19-22
Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. Biol Blood and Marrow Transplant. 2006; 12:138-151
Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O Solid cancers after allogeneic hematopoietic cell transplantation. Blood. 2009; 113:1175-1183
Durey K, Patterson H, Gordon K. Dental assessment prior to stem cell transplant: treatment need and barriers to care. Br Dent J. 2009; 206
Kumar N, Brooke A, Burke M, John R, O'Donnell A, Soldani F. The oral management of oncology patients requiring radiotherapy, chemotherapy and/or bone marrow transplantation. Facult Dent J. 2013; 4:200-203
Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood and Marrow Transplant. 2005; 11:945-956
Majorana A, Schubert M, Porta F, Ugazio A, Sapelli P. Oral complications of pediatric hematopoietic cell transplantation: diagnosis and management. Supp Care Canc. 2000; 8:353-365
Curtis RE, Metayer C, Rizzo JD, Socié G, Sobocinski KA, Flowers ME Impact of chronic GVHD therapy on the development of squamous-cell cancers after hematopoietic stem-cell transplantation: an international case-control study. Blood. 2005; 105:3802-3811
Back D, Tjia J. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes. Br J Clin Pharmacol. 1991; 32:624-626
Saif I, Adkins A, Kewley V, Woywodt A, Brookes V. Routine and emergency management guidelines for the dental patient with renal disease and kidney transplant part 2. Dent Update. 2011; 38:245-251
Darling MR, Cuddy KK, Rizkalla K. Hodgkin lymphoma of the oral mucosa. Head Neck Pathol. 2012; 6:507-510
Rosenberg A, Blesma D, Sie-Go D, Slootweg P. Primary extranodal CD30-positive T-cell non-Hodgkin's lymphoma of the oral mucosa: report of two cases. Int J Oral Maxillofac Surg. 1996; 25:57-59
Silva TDB, Ferreira CBT, Leite GB, de Menezes Pontes JR, Antunes HS. Oral manifestations of lymphoma: a systematic review. Ecancermedicalscience. 2016; 10
Aloulou S, Farhat H, Bosq J, Vanel D, Ribrag V, Turhan AG Hodgkin's disease primarily involving the oropharynx: case report and review of the literature. Hematol J. 2002; 3:164-167
Vigneswaran N, Tilashalski KR, Peters GE, Reddy VV, Rodu BK. Ulcerated tumor mass involving the right base of the tongue. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol. 1997; 84:461-464
Quiñones-Avila MdP, Gonzalez-Longoria AA, Admirand JH, Medeiros LJ. Hodgkin lymphoma involving Waldeyer ring: a clinicopathologic study of 22 cases. Am J Clin Pathol. 2015; 123:651-656
Treaba DO, Eklund JW, Wayne J, Nelson BP, Winter JN. Classical Hodgkin's lymphoma presenting with tongue involvement: a case report and review of the literature. Clin Lymph Myel. 2006; 6:410-413
Hellings P, Jorissen M, Ceuppens J. The Waldeyer's ring. Acta Otorhinolaryngol Belg. 2000; 54:237-241
Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. Blood. 2011; 117:316-322
Brody S, Omer O, McLoughlin J, Stassen L. The dentist's role within the multi-disciplinary team maintaining quality of life for oral cancer patients in light of recent advances in radiotherapy. J. 2013; 59:137-146
Oral and dental management for people with lymphoma
From Volume 46, Issue 2, February 2019 | Pages 133-150
Article
This paper offers a literature review that describes the recommended oral and dental management for people with lymphoma. From 1980 to 2017, the electronic databases, PubMed, Scopus and Google Scholar, were searched using the following keywords: lymphoma, treatment of lymphoma, monoclonal antibodies, medication-related osteonecrosis of the jaw, thrombocytopenia in relation to chemotherapy, neutropenia in relation to chemotherapy, antibiotic prophylactics, lymphoma and chemotherapy, radiotherapy and lymphoma. The search included both in vivo and in vitro studies published in the English language. The main inclusion criteria were any studies described ‘lymphoma’, ‘types of lymphoma’, ‘treatment of lymphoma’, ‘aetiology and physiology of lymphoma’, and ‘dental management of patients with lymphoma’.
Lymphoma is a solid neoplasm that arises in lymphoid tissues and spreads to distant lymphoid glands and organs.1 It occurs when abnormal lymphocytes increase in number without proper control. They divide in an abnormal pathway or do not die when they should. In 2015, the Office for National Statistics (ONS) reported that non-Hodgkin's lymphoma affected 11,690 patients, while Hodgkin's lymphoma affected 1,782 patients.2 However, in 2016, these incidences were increased to nearly 17,000 and 2,000 cases diagnosed with non-Hodgkin's lymphoma and Hodgkin's lymphoma, respectively.3 It affects any age, including children. Currently, it is mostly treatable, and people live for many years after being diagnosed.
Register now to continue reading
Thank you for visiting Dental Update and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:
What's included
- Up to 2 free articles per month
- New content available